When was Sentien Biotechnologies founded?

Sentien Biotechnologies was founded in 2008 and raised its 1st funding round 2 years after it was founded.

Where is Sentien Biotechnologies located?

Sentien Biotechnologies is headquartered in Lexington, United States. It is registered at Lexington, Massachusetts.

Who is the current CEO of Sentien Biotechnologies?

Brian Miller of Sentien Biotechnologies. They have also founded 1 company.

How many employees does Sentien Biotechnologies have?

As of Dec 31, 2021, the latest employee count at Sentien Biotechnologies is 7.

Is Sentien Biotechnologies a funded company?

Sentien Biotechnologies is a funded company, having raised a total of $13M across 5 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jun 08, 2010.

When was the latest funding round of Sentien Biotechnologies?

Sentien Biotechnologies' latest funding was a $***** Series A round on Apr 04, 2017, with participation from 5 investors. Its primary sector is Nephrology. In United States, the Nephrology sector has seen $165M in funding in 2026 to date.

Where does Sentien Biotechnologies rank among its competitors?

Sentien Biotechnologies ranks 87th amongst 462 active competitors, of which 158 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Evommune, which secured $125M in Feb, 2026.

Who are the top competitors of Sentien Biotechnologies?

Sentien Biotechnologies' top competitors include Upstream Bio, Odyssey and Septerna. Among them, Evommune secured the most recent funding round in February, 2026.

Sentien Biotechnologies - 2026 Company Profile, Team, Funding & Competitors

Sentien Biotechnologies is a series A company based in Lexington (United States), founded in 2008 by Brian Miller and Biju Parekkadan. It operates as a Developer of stem cell based device product for acute organ failure. Sentien Biotechnologies has raised $13M in funding from Boehringer Ingelheim Venture Fund and Mission BioCapital. The company has 462 active competitors, including 158 funded and 101 that have exited. Its top competitors include companies like Upstream Bio, Odyssey and Septerna.

Company Details

Sentien Biotechnologies is a pre-clinical stage regenerative medicine company that is developing cell-based therapies for acute organ failure. It has developed proprietary cell compositions and its lead product the Sentinel is being developed to treat severe Acute Kidney Injury (AKI). The company claims its product can treat patients during a dialysis dose by supplementing patient blood with MSC-derived secretions. The device is designed to be integrated into existing dialysis equipment.

Website: sentienbiotech.com
Social
Email ID: *****@sentienbiotech.com
Phone Number: +1 **********
Registered Address: Lexington, Massachusetts

Key Metrics

Founded Year

2008

Location

Lexington, United States

Stage

Series A

Total Funding

$13M in 5 rounds

Latest Funding Round

Series A, Apr 04, 2017, $*****

Investors

Boehringer Ingelheim Venture Fund & 7 more

Ranked

87^th among 462 active competitors

Employee Count

7 as on Dec 31, 2021

Similar Companies

Upstream Bio & 561 more

View Sentien Biotechnologies' full profile

Sentien Biotechnologies is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
SENTIEN BIOTECHNOLOGIES INC CIN: 263782670 , United States, Active	Dec 31, 1999	-	6 (As on Dec 31, 2023)	-

Sentien Biotechnologies has raised a total funding of $13M over 5 rounds. Its first funding round was on Jun 08, 2010. Its latest funding round was a Series A round on Apr 04, 2017 for $*****. 5 investors participated in its latest round. Sentien Biotechnologies has 8 institutional investors.

Here is the list of recent funding rounds of Sentien Biotechnologies:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 04, 2017	6574226	Series A	7346064	7713713	4613720	3826787
Aug 11, 2015	4114333	Series A	2622600	5999265	6204614	Boehringer Ingelheim Venture Fund & 1 more
Mar 02, 2014	1881169	Grant (prize money)	3012985	9682801	7618811	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Sentien Biotechnologies's funding rounds and investors

The founders of Sentien Biotechnologies are Brian Miller and Biju Parekkadan. Brian Miller is the CEO of Sentien Biotechnologies.

Here are the details of Sentien Biotechnologies' key team members:

Brian Miller: Co-Founder & CEO of Sentien Biotechnologies.
Biju Parekkadan: Co-Founder of Sentien Biotechnologies.

View details of Sentien Biotechnologies's Founder profiles and Board Members

Sentien Biotechnologies' employee count trend

Sentien Biotechnologies has 7 employees as of Dec 21. Here is Sentien Biotechnologies's employee count trend over the years:

Employee count trend for Sentien Biotechnologies

Uncover Sentien Biotechnologies' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Sentien Biotechnologies include Upstream Bio, Odyssey and Septerna. Here is the list of Top 10 competitors of Sentien Biotechnologies, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Upstream Bio 2021, Waltham (United States), Public	Developer of therapeutics for allergic and inflammatory diseases	$400M	Venrock, Enavate Sciences & 11 others	67/100
2nd	Odyssey 2018, Cambridge (United States), Public	Developer of immunotherapeutics for immunological and cancer diseases	$717M	Orbimed, Ascenta Capital & 29 others	66/100
3rd	Septerna 2020, San Bruno (United States), Public	Developer of GPCR drug discovery platform for multiple diseases	$250M	RA Capital Management, Third Rock Ventures ... & 14 others	66/100
4th	Ventyx Biosciences 2018, Encinitas (United States), Acquired	Developer of therapeutics to treat autoimmune diseases	$165M	VenBio, Logos Capital & 13 others	66/100
5th	Evommune 2020, Sacramento (United States), Public	Developer of therapeutic options for chronic inflammatory disorders	$276M	Pivotal bioVenture Partners, RA Capital Management ... & 18 others	66/100
6th	Akebia Therapeutics 2007, Cincinnati (United States), Public	Developing therapeutics solutions to treat patients with kidney disease	$91M	Genechem, Longitude Capital & 13 others	65/100
7th	CalciMedica 2006, San Diego (United States), Public	Developer of CRAC channel inhibitor drugs for inflammatory diseases	$76.7M	Biogen, Valence Life Sciences & 11 others	64/100
8th	Aurinia Pharmaceuticals 1993, Edmonton (Canada), Public	Developer of therapeutics for autoimmune diseases	-	RA Capital Management, VenBio & 10 others	64/100
9th	Alebund 2018, Shanghai (China), Public	Developer of therapeutics for kidney diseases	$114M	Morningside, Loayal Valley Capital & 14 others	63/100
10th	Enyo Pharma 2014, Lyon (France), Series C	Developer of therapeutics for diseases with impaired kidney function	$120M	Orbimed, Morningside & 9 others	62/100
87th	Sentien Biotechnologies 2008, Lexington (United States), Series A	Developer of stem cell based device product for acute organ failure	$13M	Boehringer Ingelheim Venture Fund, Chiesi Ventures ... & 6 others	45/100